Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children

dc.catalogadoraba
dc.contributor.authorSoto, J.A.
dc.contributor.authorMelo-González, F.
dc.contributor.authorGutierrez-Vera, C.
dc.contributor.authorSchultz, B.M.
dc.contributor.authorBerríos-Rojas, R.V.
dc.contributor.authorRivera-Pérez, D.
dc.contributor.authorPiña-Iturbe, A.
dc.contributor.authorHoppe-Elsholz, G.
dc.contributor.authorDuarte, L.F.
dc.contributor.authorVázquez, Y.
dc.contributor.authorMoreno-Tapia, D.
dc.contributor.authorRíos, M.
dc.contributor.authorPalacios, P.A.
dc.contributor.authorGarcia-Betancourt, R.
dc.contributor.authorSantibañez, Á.
dc.contributor.authorPacheco, G.A.
dc.contributor.authorMendez, C.
dc.contributor.authorAndrade, C.A.
dc.contributor.authorSilva, P.H.
dc.contributor.authorDiethelm-Varela, B.
dc.contributor.authorAstudillo, P.
dc.contributor.authorCalvo, M.
dc.contributor.authorCárdenas, A.
dc.contributor.authorGonzález, M.
dc.contributor.authorGoldsack, M.
dc.contributor.authorGutiérrez, V.
dc.contributor.authorPotin, M.
dc.contributor.authorSchilling, A.
dc.contributor.authorTapia, L.I.
dc.contributor.authorTwele, L.
dc.contributor.authorVillena, R.
dc.contributor.authorGrifoni, A.
dc.contributor.authorSette, A.
dc.contributor.authorWeiskopf, D.
dc.contributor.authorFasce, R.A.
dc.contributor.authorFernández, J.
dc.contributor.authorMora, J.
dc.contributor.authorRamírez, E.
dc.contributor.authorGaete-Argel, A.
dc.contributor.authorAcevedo, M.L.
dc.contributor.authorValiente-Echeverría, F.
dc.contributor.authorSoto-Rifo, R.
dc.contributor.authorRetamal-Díaz, A.
dc.contributor.authorMuñoz-Jofré, N.
dc.contributor.authorMeng, X.
dc.contributor.authorXin, Q.
dc.contributor.authorAlarcón-Bustamante, E.
dc.contributor.authorGonzález-Aramundiz, J.V.
dc.contributor.authorLe Corre, N.
dc.contributor.authorÁlvarez-Figueroa, M.J.
dc.contributor.authorGonzález, P.A.
dc.contributor.authorAbarca, K.
dc.contributor.authorPerret, C.
dc.contributor.authorCarreño, L.J.
dc.contributor.authorBueno, S.M.
dc.contributor.authorKalergis, A.M.
dc.date.accessioned2023-07-10T13:33:13Z
dc.date.available2023-07-10T13:33:13Z
dc.date.issued2022
dc.description.abstractMultiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated vaccine CoronaVac has been shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatric cohort in China. Here, we report interim safety and immunogenicity results of a phase 3 clinical trial for CoronaVac in healthy children and adolescents in Chile. Participants 3 to 17 years old received two doses of CoronaVac in a 4-week interval until 31 December 2021. Local and systemic adverse reactions were registered for volunteers who received one or two doses of CoronaVac. Whole-blood samples were collected from a subgroup of 148 participants for humoral and cellular immunity analyses. The main adverse reaction reported after the first and second doses was pain at the injection site. Four weeks after the second dose, an increase in neutralizing antibody titer was observed in subjects relative to their baseline visit. Similar results were found for activation of specific CD4+ T cells. Neutralizing antibodies were identified against the Delta and Omicron variants. However, these titers were lower than those for the D614G strain. Importantly, comparable CD4+ T cell responses were detected against these variants of concern. Therefore, CoronaVac is safe and immunogenic in subjects 3 to 17 years old, inducing neutralizing antibody secretion and activating CD4+ T cells against SARS-CoV-2 and its variants. (This study has been registered at ClinicalTrials.gov under no. NCT04992260.) IMPORTANCE This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population. Therefore, it is essential to generate knowledge regarding the protection of vaccines in this population. Along these lines, we reported the anti-S humoral response and cellular immune response to several SARS-CoV-2 proteins that have been published and recently studied. Here, we show that a vaccination schedule consisting of two doses separated by 4 weeks induces the secretion of neutralizing antibodies against SARS-CoV-2. Furthermore, CoronaVac induces the activation of CD4+ T cells upon stimulation with peptides from the proteome of SARS-CoV-2. These results indicate that, even though the neutralizing antibody response induced by vaccination decreases against the Delta and Omicron variants, the cellular response against these variants is comparable to the response against the ancestral strain D614G, even being significantly higher against Omicron.
dc.fechaingreso.objetodigital2023/07/11
dc.fuente.origenORCID
dc.identifier.doi10.1128/mbio.01311-22
dc.identifier.eissn2150-7511
dc.identifier.urihttp://doi.org/10.1128/mbio.01311-22
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/74134
dc.information.autorucFacultad de Ciencias Biológicas; Soto Ramírez, Jorge Andrés; 0000-0003-0335-9759; 237269
dc.information.autorucFacultad de Ciencias Biológicas; Melo González, Felipe Andrés; 0000-0002-3711-2407; 149763
dc.information.autorucFacultad de Ciencias Biológicas; Schultz Lombardic, Bárbara M.; 0000-0002-6201-6978; 186964
dc.information.autorucFacultad de Ciencias Biológicas; Rivera Pérez, Daniela; 0000-0002-3317-5080; 1175592
dc.information.autorucFacultad de Ciencias Biológicas; Piña Iturbe, Luis Alejandro; 0000-0001-6190-9494; 1031369
dc.information.autorucFacultad de Ciencias Biológicas; Hoppe Elsholz, Guillermo; 0000-0003-2029-9700; 1047211
dc.information.autorucFacultad de Ciencias Biológicas; Duarte Peñaloza, Luisa Fernanda; 0000-0003-1828-1800; 1031205
dc.information.autorucFacultad de Ciencias Biológicas; Moreno Tapia, Daniela; 0000-0002-2721-8355; 246324
dc.information.autorucFacultad de Ciencias Biológicas; Ríos Raggio, Mariana; S/I; 50388
dc.information.autorucFacultad de Ciencias Biológicas; Gonzalez Muñoz, Pablo Alberto; 0000-0001-7709-6870; 15616
dc.information.autorucFacultad de Ciencias Biológicas; Pacheco Ruidiaz, Gaspar Andrés; 0000-0001-5748-5027; 1047198
dc.information.autorucEscuela de Medicina; Méndez Vejar, Constanza; 0000-0002-1509-4471; 1036010
dc.information.autorucFacultad de Ciencias Biológicas; Andrade Parra, Catalina Andrea; 0000-0003-2623-1387; 234276
dc.information.autorucFacultad de Ciencias Biológicas; Silva Rodríguez, Pedro Hugo; S/I; 234277
dc.information.autorucEscuela de Química; Diethelm Varela, Benjamín Manuel; 0000-0002-5465-6924; 217234
dc.information.autorucEscuela de Medicina; Astudillo Paredes, Patricio Andrés; 0000-0002-2600-630X; 179203
dc.information.autorucEscuela de Medicina; Goldsack Gil, Macarena; S/I; 182409
dc.information.autorucEscuela de Medicina; Gutiérrez Muñoz, Valentina; 0000-0002-5815-5035; 227663
dc.information.autorucEscuela de Medicina; Potin Santander, Marcela Patricia; 0000-0003-4985-4579; 64027
dc.information.autorucFacultad de Ciencias Biológicas; Fasce Pineda, Rodrigo; 0000-0002-2213-1461; 71972
dc.information.autorucEscuela de Medicina; Valiente Echeverría, Fernando Andrés; 0000-0001-9156-2516; 1006402
dc.information.autorucFacultad de Matemáticas; Alarcón Bustamante, Eduardo; 0000-0003-3121-483X; 1050996
dc.information.autorucEscuela de Química; González Aramundiz, José Vicente; 0000-0001-7856-9211; 17164
dc.information.autorucEscuela de Medicina; Le Corre Pérez, Monique Nicole; 0000-0002-9361-4049; 6737
dc.information.autorucEscuela de Química; Álvarez Figueroa, María Javiera; 0000-0002-7978-6987; 70358
dc.information.autorucFacultad de Ciencias Biológicas; González Muñoz, Pablo Alberto; 0000-0001-7709-6870; 15616
dc.information.autorucEscuela de Medicina; Abarca Villaseca, Katia; 0000-0003-0404-3887; 70281
dc.information.autorucEscuela de Medicina; Perret Pérez, Cecilia; 0000-0002-1535-1204; 80387
dc.information.autorucFacultad de Ciencias Biológicas; Bueno Ramírez, Susan; 0000-0002-7551-8088; 113541
dc.information.autorucFacultad de Ciencias Biológicas; Kalergis Parra, Alexis Mikes; 0000-0001-7622-5263; 90610
dc.issue.numero6
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final14
dc.pagina.inicio1
dc.revistamBioes_ES
dc.rightsacceso restringido
dc.rights.licenseAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleInactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children
dc.typeartículo
dc.volumen13
sipa.codpersvinculados237269
sipa.codpersvinculados149763
sipa.codpersvinculados186964
sipa.codpersvinculados1175592
sipa.codpersvinculados1031369
sipa.codpersvinculados1047211
sipa.codpersvinculados1031205
sipa.codpersvinculados246324
sipa.codpersvinculados50388
sipa.codpersvinculados15616
sipa.codpersvinculados1047198
sipa.codpersvinculados1036010
sipa.codpersvinculados234276
sipa.codpersvinculados234277
sipa.codpersvinculados217234
sipa.codpersvinculados179203
sipa.codpersvinculados182409
sipa.codpersvinculados227663
sipa.codpersvinculados64027
sipa.codpersvinculados71972
sipa.codpersvinculados1006402
sipa.codpersvinculados1050996
sipa.codpersvinculados17164
sipa.codpersvinculados6737
sipa.codpersvinculados70358
sipa.codpersvinculados15616
sipa.codpersvinculados70281
sipa.codpersvinculados80387
sipa.codpersvinculados113541
sipa.codpersvinculados90610
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Inactivated Vaccine-Induced SARS-CoV-2.pdf
Size:
110.67 KB
Format:
Adobe Portable Document Format
Description: